Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland
NCT ID: NCT04636372
Last Updated: 2020-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2020-09-01
2021-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intense pulsed light therapy group
Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
Hot compress massage group
Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
Intense pulsed light therapy and hot compress massage group
Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any eye diseases except xerophthalmia
* No treated for xerophthalmia before
* Successful completion of follow-ups
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yune Zhao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yune Zhao
Vice president of Eye Hospital of Wenzhou Medical University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LXY-meibomian gland
Identifier Type: -
Identifier Source: org_study_id